Macrophage-based delivery of interleukin-13 improves functional and histopathological outcomes following spinal cord

Jana Van Broeckhoven1, Céline Erens1, Daniela Sommer1

  • 1Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590, Diepenbeek, Belgium.

Abstract

Insights

Genetically engineered macrophages secreting Interleukin-13 (IL-13) promoted functional recovery after spinal cord injury (SCI) in mice. This approach reduced inflammation and neuronal death, preserving tissue and improving outcomes.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Spinal cord injury (SCI) triggers neuroinflammation, involving macrophages (Mφs) and microglia, which worsens damage and hinders regeneration.
  • Pro-inflammatory Mφs/microglia contribute to secondary cell death post-SCI.
  • Reprogramming Mφs/microglia to an anti-inflammatory phenotype is a therapeutic target.

Purpose of the Study:

  • To investigate the therapeutic potential of genetically modified Mφs engineered to continuously secrete Interleukin-13 (IL-13) at the SCI lesion site.
  • To assess if sustained IL-13 delivery via Mφs can promote functional recovery and neuroprotection after SCI.

Main Methods:

  • Genetically modified Mφs (IL-13 Mφs) were created to secrete IL-13.
  • IL-13 Mφs were intraspinally injected into female mice after hemisection SCI.
  • Functional recovery (Basso Mouse Scale) and histopathology (lesion size, demyelination) were evaluated.
  • Neuroprotective effects were assessed in vitro using cell lines, neurospheroids, and organotypic brain slices.

Main Results:

  • Perilesional transplantation of IL-13 Mφs significantly promoted functional recovery in SCI mice.
  • This functional improvement correlated with reduced lesion size, demyelination, and neuronal death.
  • IL-13 Mφs suppressed axonal dieback by reducing dystrophic axon-Mφ/microglia contact.
  • IL-13 signaling via IL-4Rα was essential for the observed beneficial effects.

Conclusions:

  • Sustained IL-13 delivery via engineered Mφs can reprogram the Mφ/microglia phenotype towards an anti-inflammatory state.
  • This approach preserves neuronal tissue and reduces axonal dieback, promoting recovery after SCI.
  • IL-13 Mφs offer a promising cell-based therapy for spinal cord injury.

Related Concept Videos